CLARUS DEFINED EXIT I, L.P.

Profile

Company Names

CLARUS DEFINED EXIT I, L.P.

Addresses

101 MAIN STREET, SUITE 1210, CAMBRIDGE, MA 02142

Phone Numbers

617-949-2200

 

Entity Type:

LIMITED PARTNERSHIP

Industry:

VENTURE CAPITAL FUND

Year Incorporated:

2014

State Incorporated:

DELAWARE

Total Amount Raised:

$100,000,000.00

Number of Funding Rounds:

1
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
1
2014-07-25 
$100,000,000.00 
$100,000,000.00 
$0.00 
 
People
First Name
Middle Name
Last Name
Titles
Related Companies
N/A 
 
CLARUS VENTURES DE GP, L.P. 
DIRECTOR
CLARUS DEFINED EXIT I, L.P.   |  CLARUS DE II, L.P.
N/A 
 
CLARUS VENTURES DE GP, LLC 
DIRECTOR
CLARUS DEFINED EXIT I, L.P.   |  CLARUS DE II, L.P.
NICHOLAS 
 
GALAKATOS 
EXECUTIVE OFFICER
AFFYMAX INC   |  PORTOLA PHARMACEUTICALS INC   |  AVEO PHARMACEUTICALS INC   |  TALIGEN THERAPEUTICS INC   |  OPHTHOTECH CORP.   |  NANOSTRING TECHNOLOGIES INC   |  CATABASIS PHARMACEUTICALS INC   |  CLARUS LIFESCIENCES III, L.P.   |  CLARUS DEFINED EXIT I, L.P.   |  CLARUS DE II, L.P.   |  CLARUS IV-D, L.P.   |  CLARUS IV-C, L.P.   |  CLARUS IV-B, L.P.   |  CLARUS IV-A, L.P.   |  PRAXIS PRECISION MEDICINES, INC.   |  BLACKSTONE LIFE SCIENCES YIELD NT (CYM) FEEDER L.L.C.   |  BLACKSTONE LIFE SCIENCES YIELD L.P.   |  BLACKSTONE LIFE SCIENCES YIELD T (CYM) FEEDER L.P.   |  BLACKSTONE LIFE SCIENCES VI L.P.   |  BLACKSTONE LIFE SCIENCES VI (LUX) SCSP   |  BLACKSTONE LIFE SCIENCES VI - BL L.P.   |  BLACKSTONE LIFE SCIENCES VI - B L.P.
DENNIS 
 
HENNER 
EXECUTIVE OFFICER
SARCODE CORP   |  PROACTA INC   |  SARCODE BIOSCIENCE INC.   |  KALOBIOS PHARMACEUTICALS INC   |  AERIE PHARMACEUTICALS INC   |  CLARUS LIFESCIENCES III, L.P.   |  CLARUS DEFINED EXIT I, L.P.   |  CLARUS DE II, L.P.   |  IMAGO BIOSCIENCES, INC.   |  FORTY SEVEN, INC.   |  CLEAVE BIOSCIENCES, INC.
ROBERT 
W. 
LIPTAK 
EXECUTIVE OFFICER
CLARUS LIFESCIENCES III, L.P.   |  CLARUS DEFINED EXIT I, L.P.   |  CLARUS DE II, L.P.   |  CLARUS IV-D, L.P.   |  CLARUS IV-C, L.P.   |  CLARUS IV-B, L.P.   |  CLARUS IV-A, L.P.
SCOTT 
 
REQUADT 
EXECUTIVE OFFICER
TYRX PHARMA INC   |  TYRX, INC.   |  CLARUS DEFINED EXIT I, L.P.   |  CLARUS DE II, L.P.   |  ESSA PHARMA INC.   |  AVROBIO, INC.   |  VBI VACCINES INC/BC   |  CLARUS IV-D, L.P.   |  CLARUS IV-C, L.P.   |  CLARUS IV-B, L.P.   |  CLARUS IV-A, L.P.   |  TALARIS THERAPEUTICS, INC.
NICHOLAS 
J. 
SIMON 
EXECUTIVE OFFICER
ACHILLION PHARMACEUTICALS INC   |  PEARL THERAPEUTICS INC   |  CLARUS LIFESCIENCES III, L.P.   |  CLARUS DEFINED EXIT I, L.P.   |  CLARUS DE II, L.P.   |  CLARUS IV-D, L.P.   |  CLARUS IV-C, L.P.   |  CLARUS IV-B, L.P.   |  CLARUS IV-A, L.P.
KURT 
C. 
WHEELER 
EXECUTIVE OFFICER
ZOGENIX INC   |  SOMAXON PHARMACEUTICALS, INC.   |  CLARUS LIFESCIENCES III, L.P.   |  CLARUS DEFINED EXIT I, L.P.   |  CLARUS DE II, L.P.   |  CLARUS IV-D, L.P.   |  CLARUS IV-C, L.P.   |  CLARUS IV-B, L.P.   |  CLARUS IV-A, L.P.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2014-08-05
D
Link
VENTURE CAPITAL FUND 
 
NOT APPLICABLE 
 
2014-07-25 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#